A Prospective Trial to Identify Biomarkers Involved in the Transition From Acute to Persistent Chronic Low Back Pain

NCT ID: NCT02037763

Last Updated: 2016-09-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

5000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-12-31

Study Completion Date

2018-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective observational cohort multinational clinical study. There are no biomarkers to help predict in which patients acute low back pain (LBP) will transform into chronic low back pain (CLBP). Human variability and different common comorbidities complicate the picture and make stratification of patients into correct subgroups difficult. However, drugs act by targeting specific molecular pathways and are therefore efficient only in a subgroup of patients sharing common molecular pathology and common genetics. Both CLBP and disc degeneration are known to be heritable. Little investigation has taken place for genetic variants in CLBP. The main aim of this trial is to identify "omics biomarkers" associated with the transition from acute (single episode of low back pain) to persistent/chronic LBP (pain lasting more than 12 weeks).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Investigators will link and relate clinical data to a multiple "omics" analysis in patients developing persistent chronic symptoms (defined as pain that persists 3 months or more), after an episode of acute LBP. The development of persistent chronic pain will be assessed at 3 months after the acute episode.

"OMIC" biomarkers investigated will be genetics, epigenetics, glycomics and activomic.

Genetics through genome wide association studies (GWAS) has already obtained important results in pain research; however concerning low back pain, there is not yet suitable genotype-phenotype correlations helpful to stratify patients.

Epigenetic regulation is a universal tool that higher organisms use to adapt to changes in the environment. While environmental factors, such as diet influence enzymatic processes only while they are directly present, their prolonged effects can be achieved through the cell memory of epigenetic marks. Various elements of the membrane signal transduction system were reported to be regulated by epigenetic mechanisms.

Glycomics is an emerging field that has recently been identified as a priority for the next decade by the US National Academies of Science. Many common complex diseases will be associated with specific changes in glycan structures. In addition, common genetic polymorphisms influencing glycosylation and consequent differences in glycome composition could be important diagnostic and prognostic markers. The first studies reporting protein glycosylation in large human population samples have been recently published by partners in the consortium. Reliable identification of valid associations between specific glyco-phenotypes and predisposition for the development or progression of a specific disease requires analysis of thousands of patients.

Activomics: combines data about enzymatic activity of numerous numerous post-translational modification proteins in an integrated model which provides dynamic characterization of the current state of an organism. In this project information about numerous proteases, kinases, phosphatases and glycosidases will be collected and used to complement the existing phenotype information.

"Omics" data will be compared stratifying population according to pain characteristics, pain intensity, response to treatment and duration of pain. In a subgroup of patients, "omics" data will be compared stratifying population according to pain pathophysiology: discogenic pain, spinal stenosis, facet joint pain, sacroiliac joint pain, low back pain with radicular pain (radicular pain not predominant) and widespread low back pain.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Low Back Pain Chronic Low Back Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age: older than 18;
* acute episode of pain between the costal margins and gluteal fold, with or without symptoms into one or both legs lasting less than 6 weeks;
* written informed consent signed;
* Caucasian ancestry

Exclusion Criteria

* evidence of clinically unstable disease;
* severe psychiatric disorder (excluding mild depression) or mental impairment;
* history (in the last 6 months) of persistent chronic low back pain or acute LBP episodes
* recent history (\< 1 year) of spinal fracture;
* pain in the back due to spinal tumor or infection;
* pregnancy;
Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

GENOS

OTHER

Sponsor Role collaborator

Ip Research Consulting Sasu

INDUSTRY

Sponsor Role collaborator

Helmholtz Zentrum München

INDUSTRY

Sponsor Role collaborator

YURII AULCHENKO

UNKNOWN

Sponsor Role collaborator

King's College London

OTHER

Sponsor Role collaborator

University of Parma

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Massimo Allegri

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

MASSIMO ALLEGRI, MD

Role: PRINCIPAL_INVESTIGATOR

Pain Therapy Service Azienda Ospedaliera Universitaria Parma Italy

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Center for Clinical Research (CPI)

Winston-Salem, North Carolina, United States

Site Status RECRUITING

Edith Cowan University (ECU)

Perth, , Australia

Site Status RECRUITING

Multidisciplinary Pain Centre, Hospital Oost-Limburg (ZOL)

Genk, , Belgium

Site Status RECRUITING

"St.Catharine" Orthopedics, Surgery, Neurology and Physical Medicine and Rehabilitation Specialty Hospital (St-Cat)

Zabok, , Croatia

Site Status RECRUITING

Anesthesia and Pain Therapy Department, Università degli Studi di Parma (UNIPR)

Parma, , Italy

Site Status RECRUITING

Fondazione IRCCS Policlinico San Matteo (OSM)

Pavia, , Italy

Site Status RECRUITING

King's College London (KCL)

London, , United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Belgium Croatia Italy United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

MASSIMO ALLEGRI, MD

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

CRISTINA E MINELLA, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Pain-OMICS PRT

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Spinal Kinematics Variability
NCT03507296 COMPLETED